Erbitux Improves Survival In Metastatic Colorectal Cancer - Study Published In NEJM

Erbitux® (cetuximab), Merck Serono’s targeted cancer therapy, offers a statistically significant improvement in median overall survival compared with best supportive care (BSC), according to research published in the New England Journal of Medicine. All patients in the study had metastatic colorectal cancer (mCRC) that had progressed with all available standard chemotherapies - irinotecan, oxaliplatin, and flouropyrimidines.1The independent Phase III study NCIC CTG CO. [click link for full article]

More: continued here

Filed under: Colorectal Cancer on November 18th, 2007